Gilead (GILD) Q3 2026 Earnings Call Transcript

Gilead (GILD) reported Q3 2026 earnings, highlighting strong performance. Trodelvy sales grew 42% YoY, reaching a $2B annual run rate. HIV sales increased 18% YoY, with Biktarvy achieving a 53% U.S. market share. The company raised 2026 revenue guidance by $1.6B. Gilead also discussed pipeline advancements in oncology and inflammation, including potential approvals and clinical trials. Total product sales, excluding Veklury, were $8.2B, up 16% YoY, driven by HIV, Trodelvy, and Livdelzi.

Original reporting
Published Oct 30, 2026, 2:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Gilead (GILD) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$GILDBullishHigh
01

Why it matters

The disclosed guidance lift and sales growth provide fresh material for traders to reassess valuation.

02

Market read

First‑report earnings data for a large‑cap biotech; likely to move the stock and influence sector sentiment.

03

What to watch

Potential policy headwinds from CMS pricing decisions on Biktarvy could temper upside.

Relevance 8/10Novelty 8/10Timing: after‑hours earnings release

Background

Gilead's Q3 2026 earnings call highlighted strong performance across HIV, PrEP, oncology and liver disease pipelines, with new product launches and regulatory approvals.

Company-level read

Ticker impact

$GILDBullishHigh confidence
Context

Q3 2026 earnings call disclosed a $2 B annual run‑rate for Trodelvy, raised 2026 revenue guidance by $1.6 B and reported strong HIV, PrEP and oncology sales.

Expected impact

potential upside as market prices in higher revenue guidance

Evidence & confidence

The transcript provides first‑report numbers and a material guidance increase for a large‑cap biotech, which typically moves the stock in the same session.

Market effects

Positive momentum for biotech and HIV/oncology therapeutic segments.

U.S. biotech sector may see modest gains.

Limited to investors tracking large‑cap pharma earnings.

Counterpoint

If guidance is overly optimistic, the stock could face a pull‑back on subsequent detailed guidance.

Key entities

  • Gilead Sciences

    US‑listed biotech firm reporting Q3 2026 results.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$GSKMed

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

$GILDMed

Phase 3 Data Back ALP Normalization as Treatment Goal in PBC

Phase 3 trials show elafibranor (Ipsen) and seladelpar (Gilead Sciences) effectively normalize ALP levels in PBC patients. Both drugs were approved in 2024 for inadequate UDCA response. Trials reported significant ALP reduction and normalization rates, with safety profiles similar to placebo.

$GILDMed

Invikafusp Alfa Plus Sacituzumab Govitecan Generates Responses in Metastatic TNBC and HR+/HER2– Breast Cancer

A phase 1b/2 trial showed a 28% ORR in TNBC and 25% in HR+/HER2– breast cancer patients treated with invikafusp alfa and sacituzumab govitecan. The combination demonstrated preliminary antitumor activity with no new safety signals. Sacituzumab govitecan is FDA-approved for these indications. The trial's lead author noted the potential for deeper immune responses in historically resistant tumors.